Literature DB >> 2830927

Gene transfer into hematopoietic progenitor cells from normal and cyclic hematopoietic dogs using retroviral vectors.

M A Eglitis1, P W Kantoff, J D Jolly, J B Jones, W F Anderson, C D Lothrop.   

Abstract

The Moloney murine leukemia retrovirus-derived vector N2 was used to transfer the bacterial NeoR gene (conferring resistance to the neomycin analogue G418) into hematopoietic progenitor cells. Approximately 5% of day seven CFU-GM were resistant to 2,000 micrograms/ml G418, using a supernatant infection protocol in the absence of vector-producing cells. A greater proportion of CFU-GM colonies were recovered relative to uninfected controls as the stringency of selection was diminished. Enzyme activity was detected in drug-resistant colonies, confirming that the resistant colonies obtained after infection with N2 represented cells producing neomycin phosphotransferase. Activity in the CFU-GM colonies approached 50% of that of drug-resistant vector-producing cells on a per cell basis. To test the hypothesis that more rapidly cycling bone marrow cells would be more susceptible to vector infection, we treated progenitor cells obtained from cyclic hematopoietic (CH) dogs with the N2 vector. Despite the increased numbers of hematopoietic progenitor cells obtained from CH dogs, the proportion of G418-resistant CFU-GM did not increase over that obtained with N2-infected normal marrow. These results demonstrate that retroviral vectors can be used to transfer and express exogenous genes in canine hematopoietic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830927

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  A new retrovirus packaging cell for gene transfer constructed from amplified long terminal repeat-free chimeric proviral genes.

Authors:  Y Takahara; K Hamada; D E Housman
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector.

Authors:  S E Suter; T A Gouthro; P A McSweeney; R A Nash; M E Haskins; P J Felsburg; P S Henthorn
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

3.  Restoration of normal lysosomal function in mucopolysaccharidosis type VII cells by retroviral vector-mediated gene transfer.

Authors:  J H Wolfe; E H Schuchman; L E Stramm; E A Concaugh; M E Haskins; G D Aguirre; D F Patterson; R J Desnick; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures.

Authors:  P F Hughes; J D Thacker; D Hogge; H J Sutherland; T E Thomas; P M Lansdorp; C J Eaves; R K Humphries
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells.

Authors:  M A Bender; R E Gelinas; A D Miller
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

6.  Targeted inhibition of immunodeficiency virus replication in lymphocytes through retroviral mediated gene transfer.

Authors:  F Y Tung; M D Daniel
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.